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a  b  s  t  r  a  c  t
The  long-term  outlook  for regenerative  medicine  predicts  an  increased  need  for scalable  cell expansion
technologies  that  utilize  non-animal  derived  materials  and  are  compatible  with  the  limited  number  of
downstream  processing  steps  required  for cell-based  therapies.  As  more  stem  cell  therapeutics  progress
through  clinical  testing,  current  in  vitro  culture  methods  using  planar  vessels  are  proving  cumbersome  to
scale.  Therefore,  alternative  processes  are  under  investigation.  Many  human  mesenchymal  stem/stromal
cell (hMSC)  bioreactor-based  manufacturing  processes,  in  particular,  are  complicated  by  the require-
ment to separate  cells  from  microcarriers  with  high  cell  yield  and  viability  whilst  maintaining  target




development  for the  expansion  of cellular  therapeutics,  with  focus  on  allogeneic  hMSCs  and  microcarrier-
based  processes.  Upstream  challenges  include  the  interplay  between  the  cell  culture  substrate  and  media
formulation,  sourcing  of  high  quality  animal-free  reagents,  and  considerations  for the  use  of microcar-
riers  in  stirred-tank  systems.  Complications  in  downstream  processes  include  harvest  approaches  for
separation  of cells  from  microcarriers  and  volume  reduction.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Stem cell-based therapies are distinct from traditional biophar-
aceuticals in that the cell itself is the ﬁnal treatment product
ather than simply the means by which to produce a drug sub-
tance. Stem cells injected into a patient may  engraft and/or secrete
olecules that elicit an endogenous response. The injection is a
omplex therapeutic that must be administered in a certain func-
ional state and can be inﬂuenced by the microenvironment or
iche [1,2].
There are two categories of cellular therapeutics: autologousnd allogeneic which can also be described as patient-speciﬁc
nd universal donor, respectively. For an autologous therapy, the
ndividual donor is also the recipient of the treatment termed a
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“one-to-one” therapy. In the allogeneic approach, a single donor
provides primary cells used to produce the therapeutic cells that
will be administered to many recipients; thus considered a “one-to-
many” therapy. Autologous and allogeneic therapies each require
distinct criteria in order to meet manufacturers’ and patients’
needs. Autologous applications may  require expansion of cells prior
to administration; thus the scaling of these technologies is consid-
ered “scale-out” where many donors’ cells may  be processed in
parallel. Key needs for autologous expanded cells are automated
and closed manufacturing, as well as faster testing of the drug sub-
stance. Cell expansion is required for allogeneic therapies in order
to generate ready-to-use doses for multiple patients; these are con-
sidered “scale-up” applications, calling for larger volumes to meet
lot size needs. Key needs for allogeneic expanded cells are scalable
expansion vessels up to 1–2kL with similar downstream process-
ing capabilities [3,4]. There are examples of cell therapies that cross
these commonly used descriptors, such as a cord blood transplants
that are one-to-one, but in fact can be used in non-matched recip-
ients. In all instances, cGMP grade raw materials, including serum
replacement and ideally chemically-deﬁned media, are important
for ensuring that the highest quality product is manufactured.
There are a growing number of clinical and commercial activi-
ties in the cell therapy space including hundreds of global trials and
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).



















































iFig. 1. A process for the manufacturing of a cellular therapeutic. Major chal
arketed products for “stem cells”, excluding gene modiﬁed thera-
ies [5]. The vast majority of these employ adult, multipotent cells,
uch as human mesenchymal stem/stromal cells (hMSCs). Whereas
any of the ﬁrst cell therapy applications treated musculoskele-
al and skin diseases, some of the most promising applications
nclude those for acute diseases, such as cardiovascular or stroke
vents, and immunological dysfunction. Celyad (formerly Cardio3
iosciences) is using hMSCs differentiated to a cardiac progenitor
ineage in a phase 3 clinical trial to treat congestive heart failure
6]. Osiris Therapeutics recently divested their culture-expanded
MSCs to Mesoblast, and continues to investigate autologous appli-
ations in cell therapy [7], while Mesoblast has a phase 3 trial
pplication for graft versus host disease using the expanded hMSCs
8]. Although a joint Athersys-Pﬁzer phase 2 trial did not ﬁnd a sig-
iﬁcant effect of undifferentiated bone marrow-derived hMSCs on
lcerative colitis at midpoint outcomes, the safety proﬁle of ﬁrst
ound dosing was favorable and the trial continued to second round
osing and later time points [9,10]. Athersys is also evaluating these
ells as possible treatment for other indications including ischemic
troke [11].
Challenges in generating cells for therapeutics include the lack
f scalable, cost-effective systems utilizing processing equipment
n which the product is not exposed to the immediate room envi-
onment (i.e., closed systems). In order to affect this sort of system,
olutions that ensure patient safety, operator ease of use and lot-
o-lot reproducibility in the ﬁnal product must be implemented.
here has been intense focus on increasing scale and yield in order
o drive down costs [3]; however, another avenue that can be inves-
igated is to increase the potency of the cells produced. With a
rue understanding of the mechanism of action, the production of
ells with speciﬁc quality attributes can be directed, thus requir-
ng fewer cells for the same treatment. The result is a lower cost
f goods and smaller batch size requirement. Both development
f scalable manufacturing solutions and improvement of potency
f the cells should be pursued in order to ensure the successful
mplementation cell therapy treatments.
The large-scale industrialization of stem cell production for
heir use as therapeutics (Fig. 1) presents several opportunities
or manufacturers to develop regulatory-compliant, cost-effective
rocesses. As discussed herein, it is clear that movement away from
lanar culture and towards stirred tank bioreactors where suspen-
ion culture using microcarriers is enabled, will be a requirement
4]. The bulk of current work to transition hMSCs to stirred tank
ioreactors leverages microcarriers, however the growth of hMSCs
s aggregates has also been described [12,13]. More recently,
limperti et al.demonstrated the culture of hMSC spheroids in
mall-scale suspension culture [14]. Although this approach will
ot be discussed in detail, many of the concepts herein concerning
eagent and process optimization may  also be relevant to hMSC
xpansion in stirred systems without microcarriers. A complete
ingle-use, end-to-end, manufacturing process is attractive due to
ts lower overall start-up cost versus traditional stainless steel pro- remain in all stages; in particular harvest, formulation and transportation.
cesses, its inherent ﬂexibility and adaptability to the emerging
requirements of cell-based therapeutics, and the scale required.
Some of the difﬁculties to this approach include ensuring that
all components interacting with the process stream are low in
extractables, do not contain materials derived from animal sources
or at least comply with established regulatory guidance on mini-
mizing the risk of transmitting animal spongiform encephalopathy
as described in EMEA/410/01, while at the same time meeting the
requirements of cell yield and performance. It should be noted that
these are of critical importance as the cells undergo minimal pro-
cessing before introduction into patients.
2. Scale-up approaches
2.1. Transition from planar to microcarrier-based systems
Adherent cell expansion has traditionally been performed on
planar surfaces such as well-plates and tissue culture ﬂasks for
simplicity and easy handling when large numbers of cells are not
required. For larger scale expansion, multi-layered ﬂasks, spinner
ﬂasks and bioreactors offer higher capacity (available technolo-
gies summarized in Table 1); however, optimal culture conditions
for stem cells are still under investigation [15] and will certainly
depend on each particular cell type. In addition, there is concern
regarding the population doublings required for expansion of cells
to sufﬁcient quantities to meet target dose requirements [16]. There
are challenges with growing stem cells in multi-layered ﬂasks as
these vessels are cumbersome and time-consuming to handle, have
limited scalability and typically limit the user’s ability to monitor
cell health or marker status during cultivation. Transitioning from
planar-based culture to microcarrier-based systems not only allows
for higher density culture, and thereby cost of goods reduction, but
also for more stringent culture control and monitoring.
The transition to bioreactors allows for greater process control
since samples can be collected during and following the expansion
process and characterized by off-line analytics such as ﬂow cytom-
etry which aids in optimizing the process. In order to retain the
functional characteristics of hMSCs, the passage numbers and cell
doublings are monitored and minimized [17]. MSCs expanded both
in planar and suspension formats are commonly evaluated for cell
identity and purity by criteria outlined by the International Soci-
ety for Cellular Therapy [18] as well as the International Federation
of Adipose Therapeutics and Sciences [19], yet these criteria may
not always be indicative of function [20]. Apart from these rec-
ommended criteria, there are additional markers which are used
by several researchers in the stem cell ﬁeld, often with the goal
of isolating or deﬁning a more homogeneous population of cells
[21–23]. Moreover, a broad range of functional assays are employed
to determine whether expanded hMSCs have maintained differen-
tiation potential, cytokine release, immune modulation, migration

















Summary of available single-use cellular expansion technologies. Approximate surface areas for suspension systems are based on 15 g/L of a 360 cm2/g microcarrier.
Technology  Volume  Surface  area  (approx.
cm2)
Example  technologies  Features
T-ﬂasks  (single  layer/≤5
multilayers)
30  mL/200  mL  150/1000  Vented  ﬂasks  (Corning)/Millicell® HY  multilayer  culture  ﬂasks  (EMD  Millipore)  -  Small  scale
- High  volume:area  ratio
- No inline control  or  monitoring
Multilayer stacks  (10/40  stack
layers)
1.4 L/5.5  L 6,360/25,440  CellSTACK® cell culture  chambers  (Corning),  Nunc  Cell  FactoryTM systems  (Thermo  Scientiﬁc)  -  Single-batch  expansion
-  Small  scale
- High  volume:area  ratio
- No inline control  or  monitoring
- Cumbersome  at  larger  scale,  may  require  robotic  handling
Closed system,  multilayer
stacks  (12/36/120  layers)
1.3  L/3.9  L/13  L 6,000/18,000/60,000  HYPERFlask® Cell  Culture  Vessels  (Corning)  -  Single-batch  expansion
-  Condensed,  gas-permeable  culture  layers
- Closed  venting/gassing
- Lower  volume:area  ratio  than traditional  stacks
- No inline control  or  monitoring
- Cumbersome  at  larger  scale,  may  require  robotic  handling
Spinner ﬂasks  125  mL–  3  L 675/2700  Corning® Disposable  Spinner  Flasks  (Corning)  -  Suspension  systems offer  lower  volume:area  ratio  than planar  culture
- Suitable for  small-scale  process  development  and expansion
- Surface  aeration  only
-  No inline monitoring
Mini-reactor systems  3–250 mL  16–1,350  DASbox®Mini Bioreactor  System  (Eppendorf),  BioLevitatorTM 3D Cell  Culture  System  (Hamilton),  TAP  ambrTM
microbioreactor (Sartorius),  Micro-24  MicroReactor  System  (Pall  Corporation)
-  Suitable for  small-scale  process  development  with  up  to  24  parallel  reactors
- Small  footprint
- Controlled  gassing
- Inline  monitoring
- BioLevitatorTM exclusively  used  with  GEMTM magnetic  microcarriers
Benchtop stirred  reactors  1 L–5 L 5,400–27,000  Mobius®  CellReady  (EMD  Millipore),  CelliGen® BLU (Eppendorf),  UniVessel® SU (Sartorius)  -  Suitable for  small-scale  process  development  and expansion
- Controlled  gassing
- Inline  monitoring
Pilot scale,  stirred  reactors  50  L–300  L 2.7 ×  105–1.62  × 106 Mobius®  CellReady  (EMD  Millipore),  CelliGen® BLU (Eppendorf),  BIOSTAT® STR  (Sartorius),  XcellerexTM XDR (GE
Healthcare), HyPerformaTM Single-use  Bioreactor  (Thermo  Scientiﬁc),  NucleoTM Single-use  Bioreactor  (Pall
Corporation), AllegroTM STR  200  (Pall  Corporation)
-  Suitable for  pilot  scale  and  clinical  scale  manufacturing
- Many  systems  scalable  from  lower  volume  offerings
- Controlled  gassing
- Inline  monitoring
Production scale,  stirred
reactors
500  L–2000  L 2.7 ×  106–1.08  ×  107 BIOSTAT®  STR  (Sartorius),  XcellerexTM XDR (GE  Healthcare),  HyPerformaTM Single-use  Bioreactor  (Thermo  Scientiﬁc),
NucleoTM Single-use Bioreactor  (Pall  Corporation)
-  Suitable for  clinical  scale manufacturing
- Many  systems  scalable  from  lower  volume  offerings
- Installation  of large  scale  single-use  bags  is  cumbersome
- Controlled  gassing
- Inline  monitoring
Oscillating motion  reactors,
surface  aeration  only
300–500L  1,620–2.7  × = 106 WAVE  bioreactorTM system  (GE  Healthcare),  BIOSTAT® RM (Sartorius),  SmartBagTM containers  (Finesse),  AppliﬂexTM
systems (Applicon),  CELL-tainer® (CELLution  Biotech/Lonza),  XRS-20  Bioreactor  System  (Pall  Life  Sciences)
-  Suitable for  development  to  clinical  scale  manufacturing
- Many  systems  scalable  from  lower  volume  offerings
- No sparging
-  Inline  monitoring
Oscillating motion  reactors,
sparging
30–1000  L  162,000–5.4  × 106 BaySHAKE® (Bayer)  -  Suitable for  development  to  clinical  scale  manufacturing
- Many  systems  scalable  from  lower  volume  offerings
- Gas transfer  via sparging
-  Inline  monitoring
Vertical wheel/bubble  column  50–500  L 270–2.7  ×  106 Vertical-WheelTM reactor  (PBS),  CellMaker  PLUSTM system  (Cellexus)  -  Suitable for  development  to  clinical  scale  manufacturing
- Gas transfer  via sparging
-  Mixing  by  air-  or  magnetic-driven  wheel
- Inline  monitoring
Pilot scale,  static  19.8  L 1.15 ×  105 IntegrityTM XpansionTM Multiplate  (Pall Corporation)  -  Suitable for  development  to  small  scale  manufacturing
- Growth  on planar  surface
- Gentle  media  circulation  and  gas  transfer
- Requires  large  incubator  for  temperature  control
- Inline  monitoring
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.2. Attachment surfaces for microcarrier-based systems
Microcarriers enable culture of adherent cells in suspension sys-
ems by providing suitable attachment surfaces while suspended
n the culture medium via agitation. Microcarriers offer the advan-
age of a large surface to volume ratio, facilitating higher density
ultures. They help alleviate some of the problems associated with
tatic cultures including the large volumes of media required, inef-
cient gas transfer, the presence of concentration gradients, as
ell as inadequate monitoring and control [24]. The majority of
urrently available microcarriers are spherical in shape, but cylin-
rical (DE53, Whatman) and disc-shaped (Fibra-Cel®, Eppendorf)
icrocarriers are also available. Microcarriers can be manufac-
ured from a variety of base materials including glass, polystyrene,
lginate, cellulose, dextran or gelatin, and can be macroporous or
icroporous, the latter of which will be the focus of this review.
erivatizing microcarriers to carry charges, peptides or extracellu-
ar matrix proteins such as collagen, ﬁbronectin and laminin can
nhance cell attachment and promote growth. Collagen, a major
omponent of extracellular matrix (ECM), is also commonly used
s a surface coating for hMSCs grown on microcarriers. Although
nimal-free collagens are becoming more readily available, many
ollagen coatings are still derived from animal sources. Additional
nimal-free options include laminin, poly-d-lysine, ﬁbronectin [25]
nd derivatives thereof, such as superﬁbronectin [26]. The surface
haracteristics of the microcarrier are paramount in determining
ts performance with respect to cell attachment, proliferation and
o some extent differentiation. The GEMTM magnetic microcar-
ier is used speciﬁcally with the small-scale BioLevitatorTM system
y Hamilton, and potentially provides low shear suspension and
dditional options for cell—microcarrier separation during culture
arvest, though available surface coatings and chemistries are lim-
ted in this format.
Components from serum used to supplement cell culture media,
uch as ECM proteins, can nonspeciﬁcally bind to the micro-
arrier surface and thereby aid in cell attachment. The surface
roperties of the microcarrier will determine which ECM proteins
ill bind, and thus the selection of an appropriate microcar-
ier/coating combination is essential for optimal performance. For
xample, positively charged microcarriers will selectively bind
lbumin whereas gelatin-coated microcarriers will preferentially
ind ﬁbronectin [27]. Both low-serum and ECM protein coating
ere shown to be essential for cell attachment in serum-free
edia [28,29]. Ideally, cell culture media should be optimized for
se with standard tissue culture-treated surfaces, though this is
ertainly cell type-dependent and can result in a decline in differ-
ntiation potential in comparison to collagen-coated surface [30].
ynthetic surfaces have also been developed that support cultiva-
ion of hMSCs in serum-free media [31].
Current investigations concerning the use of engineered sur-
aces suggest that the planar structure, including stiffness,
anotopography and local curvature of the material, can impact
roliferation, maintenance of phenotype and differentiation [32].
or example, it has been demonstrated that small changes in
anoscale features can either promote maintenance of stemness or
steogenesis in hMSCs [33]. Soft gels were demonstrated to sup-
ort hMSC differentiation to neuronal cells, whereas stiffer gels
upported an osteoblast-like phenotype [34]. Although the effect
f the biomechanical properties has thus far primarily been eval-
ated on ﬂat culture surfaces, it is likely they also play a role in
icrocarrier-based cell culture. The biochemical and biomechani-
al properties of surfaces could be potentially leveraged to improve
he efﬁcacy of stem cell culture.
A key consideration in microcarrier-based culture is whether the
ulture conditions support the transfer of cells from one microcar-
ier to another [35]. This migration of cells from “bead-to-bead” iseering Journal 108 (2016) 3–13
likely inﬂuenced by an interplay between the cell type, media com-
position and microcarrier surface. Whether a given system supports
cell transfer between microcarriers can be determined by adding
new microcarriers to an existing culture and observing the trans-
fer of cells. Routine monitoring of the culture helps determine the
need for additional surface area in the form of fresh microcarriers
for continued growth. In systems that do not support bead-to-bead
migration of cells, enzymatic detachment can be performed within
the vessel prior to the addition of new microcarriers and continu-
ation of the culture.
2.3. Suspension culture vessels
A major challenge to stem cell-based therapy is the ability to
generate the number of cells required to make its application prac-
tical and cost-effective. A variety of bioreactor vessels have been
used with microcarriers to increase stem cell production for cell
therapy (Table 1), including stirred-systems such as spinner ﬂasks
and stirred-tank bioreactors, and non-stirred systems such as oscil-
lating and multiplate bioreactors. The Mobius® 3 L Bioreactor was
the ﬁrst single-use stirred-tank bioreactor reported to success-
fully expand hMSCs on microcarriers [36]. It was  demonstrated
that a yield of approximately 600 million hMSCs was obtained in
a 2.4 L working volume using collagen-coated polystyrene micro-
carriers; these cells retained their basic deﬁning characteristics of
cell surface marker expression and differentiation potential. hMSCs
have been successfully expanded in other stirred systems, such
as the 1.3 L Bioﬂo® reactor in which approximately 1.4 × 105 and
6.0 × 104 cells/mL of bone marrow-derived and adipose-derived
hMSCs were achieved, respectively [37]. Additionally, hMSCs have
been expanded in the Biostat® B 1 L and 5 L reactors, and also
retained phenotypic features after post-harvest from the micro-
carriers [38,39].
Using a non-stirred system Timmins et al. reported the expan-
sion of placental hMSCs in a Wave bioreactorTM system using
macroporous gelatin microcarriers [40]. Wave-mixed bioreactors
rely on rocking motion to create a wave for mixing and bubble-free
aeration. The rocking angle and rate must be carefully tuned to meet
the changing gas transfer needs of a growing culture (reviewed
in Ref. [41]). Conversely, in a parallel plate bioreactor such as the
IntegrityTM XpansionTM Multiplate Bioreactor (Pall Corporation),
cells remain stationary on the culture surface while the medium
is circulated throughout the vessel. The XpansionTM bioreactor is
made of stacked circular plates, reminiscent of multitray 10-stack
planar ﬂasks. The system additionally enables control of pH and
dissolved oxygen (DO) with installed sensors and inlets/outlets for
gases. This type of hybrid system may  be particularly well-suited for
cells that cannot tolerate the hydrodynamic forces when attached
to a microcarrier [42], though does not enable sampling of cells
during the bioreactor run.
Single-use technologies are particularly amenable to cell-based
therapeutics due to their ﬂexibility and low start-up costs as
compared to traditional stainless steel systems, and potential
alleviation of sterility concerns [4]. Several scalable, single-use
bioreactors from various manufacturers are currently available
which are capable of processing up to 2000 L of cell culture (Table 1).
Since single-use technology, by its very nature, lends itself to
facile customization, the application of single-use bioreactors to
microcarrier-based stem cell manufacturing offers the possibility of
customization designed to meet the unique (e.g., low hydrodynamic
stress) requirements of a particular manufacturing process. Other
single-use technologies, which have been established for many tra-
ditional cell-based recombinant protein manufacturing processes
can be readily applied to regenerative medicine applications such
as containers for preparation of media, buffer and microcarriers,
customizable storage and transport bags, containers for collection
A.C. Schnitzler et al. / Biochemical Engin
Fig. 2. Factors inﬂuencing hydrodynamic forces exerted on cells in a stirred-tank











































frowth and viability of the cultures stem cells. The choice of microcarrier (e.g., size,
ensity, porosity etc.), impeller speed and gassing strategies must be considered
ogether in order to ensure success in any particular stirred-tank bioreactor.
nd storage of cells and validated sterile-to-sterile connectors. The
vailability of pre-sterilized single-use components is particularly
ttractive in autologous stem cell applications, where the culture
olumes used for production are relatively small. Many of the cur-
ent challenges that exist in implementing stirred-tank bioreactors
or microcarrier-based manufacturing processes can be addressed
y partnering with manufacturers of single-use technologies.
.4. Culture of adherent cells in stirred systems—effects of ﬂuid
ynamics
Identiﬁcation of the proper impeller speed is critical for opti-
ization of ﬂuid dynamic conditions for microcarrier processes in
tirred-tank bioreactors. For microcarrier processes, it is desirable
o maintain a homogeneous state of suspension to ensure a uniform
rowth environment throughout the entire vessel. However, since
he sensitivity of cells to hydrodynamic shear forces that can cause
amage resulting in cell lysis or decreased biopharmaceutical pro-
ein productivity [42] can be exacerbated when cells are grown on
icrocarriers [43,44], microcarrier users develop their processes
ith agitation rates that are as low as practically possible. Balancing
hese factors against the need to keep the microcarriers adequately
uspended, while also maintaining sufﬁcient bulk liquid mixing for
ppropriate aeration of the culture, can be challenging. Factors that
ay  inﬂuence the hydrodynamic forces exerted on cells cultured
n microcarriers in a stirred-tank are summarized in Fig. 2. These
actors are highly dynamic and interconnected, and the relative
mportance of each factor can vary greatly depending on process
peciﬁcs.
Identiﬁcation of the minimum agitation requirement for micro-
arrier suspension is of utmost importance to ensure successful cell
ulture. If the impeller speed is too low, the microcarriers do not
irculate in the medium and cell growth is poor [45]. While mixing
nd ﬂuid dynamics in bioreactors have been studied extensively,
he focus has been on liquid–liquid and gas–liquid interactions. The
uspension of solid particles in liquid media has received consider-
bly less attention [46]. To date, the empirical correlation derived
y Zwietering in 1958 [47] is still the most widely-used method to
haracterize microcarrier suspension [46,48]. This method allows
or the determination of Njs, or the minimum impeller speed
o maintain complete suspension, ensuring that no microcarriers
emain on the bottom of the vessel for more than 1 to 2 s [47].
his Njs is typically used as the minimum agitation requirement
or microcarrier processes. At Njs, the microcarrier concentrationeering Journal 108 (2016) 3–13 7
will normally decrease with height and could fall to zero near the
surface. As the impeller speed is increased to above Njs, the micro-
carrier distribution approaches homogeneity. At speeds far below
Njs, microcarriers fall out of suspension, with microcarriers settling
in areas of low ﬂow at the bottom of the vessel. Such conditions
result in poor cell growth due to the decreased microcarrier sur-
face area in contact with the medium. It has also been observed
that inadequate agitation can result in overgrowth of cells (forming
bridges between microcarriers) [45]. This phenomenon is partic-
ularly prevalent towards the end of the culture cycle, due to the
increase in particle density as cells begin to populate the surface
of microcarriers. While it has not been extensively studied, Clark
and Hirtenstein suggest that the best results are generally obtained
by changing from lower to higher agitation rates as the culture
progresses [45].
Identifying the upper agitation limit is as critical to a successful
microcarrier process as identifying the lower agitation limit. High
levels of shear stress can inhibit culturing of cells in stirred-tank
bioreactors, since the cells adhering to the microcarrier surface are
more sensitive to ﬂuid-mechanical forces than freely-suspended
single cells [49,50]. Damage incurred on microcarrier cultures have
been investigated based on the Kolmogorov turbulence model
described in 1941. In microcarrier culture, turbulent eddies are
often intermediate in size between the cells and the microcarriers,
and the high rate of local energy dissipation due to these eddies
interacting with the surface of microcarriers can cause shear rates
that are sufﬁciently large to damage or even remove cells from the
microcarrier surface [51]. Little work has been done to apply the
Kolmogorov model directly to hMSCs grown on microcarriers in
stirred-tank systems, though Hewitt et al. have leveraged the the-
ory to interpret a study examining the impacts of impeller design
and microcarrier concentration on hMSC growth in spinner ﬂasks
[52].
Estimates of shear stress that can promote aggregate and/or
embryoid body formation for a variety of stem cell types has
been described [50] and support the need to develop systems and
processes imparting minimal hydrodynamic shear. Studies of the
impact of hydrodynamic forces (i.e., energy dissipation rate) using
a ﬂow contraction device on suspension cells [53] suggest cells to
be more resistant to the lethal effects of shear than anticipated.
However, direct characterization of hMSCs in this manner, which
are thought to be substantially more sensitive to shear than CHO
cells, has not as yet been reported. Therefore, the determination
of an optimal impeller speed range for hMSC growth on microcar-
riers in any stirred-tank system requires an empirical analysis to
balance performance versus hydrodynamic forces. Using too low
a speed will result in microcarrier settling, aggregation and poor
process control. In contrast, too high a speed may  result in hydro-
dynamic shear forces that have been shown to inﬂuence phenotypic
characteristics of hMSCs including cell signaling and differentiation
[54,55]. The choice of microcarrier is critical and users should con-
sider their size in relation to the Kolmogorov eddy length, density in
relation to settling, as well as their composition and surface area in
order to optimize stem cell production in stirred-tank bioreactors.
It will be critical to choose impeller speeds that not only support
cell growth but also enable the cells to maintain stem cell identity
and potency.
2.5. Controlling dissolved oxygen
Hypoxic culture conditions may  provide solutions to overcome
problems observed in regenerative medicine for hMSCs; for exam-
ple, poor growth kinetics, genetic instability and poor engraftment
after transplantation. Traditional cell culture is performed under
normoxic oxygen concentration (21% O2 in ambient air). However,
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ivation of hMSCs as they are derived from tissues that vary in
xygen tension (e.g., 1–7% in bone marrow and 10–15% in adipose
issue) [56–58]. Using umbilical cord-derived hMSCs, Lavrentieva
t al. found that self-renewal capacity of different hypoxic hMSC
opulations was increased compared to the normoxic culture, and
MSCs cultured under hypoxic conditions still maintained their
ifferentiation properties [59]. The same group then further ana-
yzed the expression of oxygen-dependent cytokines from hMSCs
o link the proliferation and differentiation capacities [60]. It was
ound that growth factors and growth factor receptors were both
ver-expressed under hypoxic conditions, whereas differentiation
actors were absent under both hypoxic and normoxic condi-
ions. It was concluded that the enhanced growth potential and
aintained undifferentiated status can be attributed to the oxygen-
ependent expression of a particular set of cytokines. The effects
f hypoxic culture for MSCs were well-reviewed by Haque et al.
61], and also by Sart et al.,describing how oxygen tension interacts
ith glucose levels to inﬂuence proliferation and differentiation
62].
Considering the numerous studies in planar culture that sug-
est some effect of oxygen tension of MSC  characteristics, more
xtensive studies will be required to fully understand the oxygen
equirements of hMSCs expanded in suspension-based systems.
n a stirred-tank bioreactor, effective expansion of hMSCs was
btained under hypoxic conditions at 20% and 9% air saturation (4%
nd 2% oxygen, respectively) controlled via sparging, with no signif-
cant differences in growth, glucose or lactate levels [37]. Moreover,
hen controlled gassing is not applied, dissolved oxygen levels can
rift down as the culture progresses. As much as a 50% drop in oxy-
en has been measured during hMSCs expansion in a stirred-tank
ioreactor in which oxygen levels were monitored but not con-
rolled [39]. In most single-use stirred tank bioreactors there are
ifferent options to control DO such as overlay, open pipe sparg-
ng and microsparging. Of them, an overlay is the least intrusive
ethod and generally used for low cell density culture or low oxy-
en uptake rate cells. Open pipe is generally used to strip carbon
ioxide in the system, whereas microsparging is more effective
or oxygen transfer, especially during high cell density cultivation.
parging paradigms in order to meet gas transfers demands must
lways be balanced with the possible generation of foam that can
dversely affect the culture health. Although there is a body of work
egarding oxygen levels and hMSCs in planar culture or for example
D scaffolds [63], bioreactors introduce the opportunity not only to
urther characterize optimal oxygen levels, but also to determine
he best method for that control.
. Cell culture media and supplements
.1. Fetal bovine serum—nutrient content and material sourcing
Fetal bovine serum (FBS) is commonly used as a supplement to
ell culture media. It provides high concentrations of growth stim-
latory factors, macromolecules, carrier proteins for lipids, trace
lements, attachment and spreading factors, low molecular weight
utrients, hormones, and low concentrations of immunoglobins
64]. However, there are issues with the use of serum such as
ost, availability, non-desirable/undeﬁned components, lot-to-lot
ariability and the risk of transmission of Bovine Spongiform
ncephalopathy (BSE) and/or viral pathogens. In addition, there are
thical concerns around the harvest and collection of fetal bovine
erum [65]. Traceability and origin are important for FBS used in
ommercial processes. “Origin” is the country in which the raw
aterial is collected. “Traceability” refers to the documentation
oadmap that connects the serum’s origin to ﬁnal manufacturing
nd distribution. The United States Department of Agriculture per-eering Journal 108 (2016) 3–13
mits the importation of bovine products only from those countries
that are considered to be at low risk for BSE, such as Australia and
New Zealand that together with the United States, supply 90% of
the serum used for commercial therapeutics [66].
As described by Brindley et al., the current global FBS supply
may  not be able to support the manufacturing of multiple success-
ful cell therapies [66]. There are limited suppliers with international
standards organization (ISO)-grade environments for collection of
serum suitable for cell therapy production. The authors go on
to describe the declining global serum supply, following reduced
demand from the vaccine industry that is transitioning to expres-
sion systems using serum-free mammalian or microbial platforms.
They estimate that current production is at approximately 600,000
liters per year of which only 200,000 liters may  be suitable for
cell therapy production. Cell therapy manufacturing demand on
the other hand, is on the rise; thus, the serum infrastructure may
not be able to meet the demands of the projected cellular therapy
market. A serum supply of 200,000 L is predicted to support pro-
duction of 400,000 therapeutic doses per year. After that xeno-free
or serum-free manufacturing strategies will be necessary to sustain
the growth of the cellular therapy market.
3.2. Platelet lysate as a serum alternative
Various blood products derived from mature organisms have
been investigated as suitable substitutes for FBS to support
the hMSC cultivation, including antagonist-activated platelet-rich
plasma and platelet lysate; these materials contain elements essen-
tial for cell expansion [64,67]. Platelets isolated from whole blood
donations or by apheresis originating from single or multiple
donors are used to produce human platelet lysate (hPL) via multiple
freeze-thaw cycles to release large quantities of growth factors that
support hMSC expansion [68]. Less processed forms of hPL require
the use of animal-derived heparin to prevent coagulation, whereas
other hPL forms go through reﬁning steps to inhibit the effect of
clotting factors. Moreover, an inactivation process involving pso-
ralen and UVA light can be applied to the platelet lysate to help
prevent donor-derived pathogen transmission [68]. hPL has low
levels of insulin-like growth factor 1 (IGF-1) and protein content
compared to human serum, likely due to removal of immunoglob-
ulins and albumin [64], yet retains high levels of key growth factors
including basic ﬁbroblast growth factor (bFGF) and transforming
growth factor-1 (TGF-1) [69]. It supports the expansion of hMSCs
without additional supplementation of recombinant growth fac-
tors as is typical of FBS-containing media [70]. Obviating this need
for exogenous growth factor supplementation may  help reduce
costs.
Reported advantages of using hPL in place of FBS in media
include a reduction of cell culture duration as a result of shorter
doubling times [70,71] and a potentiation of the inhibitory effects
of adipose-derived hMSCs on lymphocyte proliferation when the
hMSCs were expanded in hPL-containing media [72]. Whereas hPL
may  offer advantages from a safety perspective since the source
material is animal origin-free and approved for human use, the
use of human-derived component presents other potential risks
[15,73] as routine screening of blood may  be insufﬁcient to provide
the required level of safety. Moreover, hPL often requires the use of
animal-derived heparin to prevent coagulation, though there are
heparin-free preparations available. Additional concerns include
security of supply and batch-to-batch variation which could impact
the adoption of hPL in clinical-scale production. The concerns raised
from use of FBS or human-sourced supplements like hPL, suggests
the need for the development of chemically deﬁned media for cul-
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.3. Formulating chemically-deﬁned media
Widely varied media formulations have been tested with
ixed results on hMSC proliferation and maintenance of func-
ional attributes (reviewed in [74]), the vast majority of which
ontain blood-derived components. One of the major compli-
ations in formulating cell culture media without the use of
nimal or human-derived products is replacement of serum
lbumin. This pleiotrophic blood protein carries a multitude
f molecules that support and/or stimulate stem cell growth.
n addition, albumin binds and tempers the potentially toxic
ffects of common culture additives such as antibiotics, and pro-
ides a degree of buffering capacity that helps regulate culture
onditions. Although recombinant forms of the protein retain
any of these beneﬁcial properties, they lack critical albumin-
ssociated molecules such as lipids, hormones and trace elements.
ipids, mainly fatty acids and sterols, are present in published
erum-free formulations such as TeSR1 [75], and have long been
ecognized as essential for the cultivation of mammalian cells
nder serum-free conditions. Primary cells such as hMSCs pose
 great challenge when transitioning away from FBS-containing
edium as they are not immortalized, have limited replication
apacity and may  not adapt well to minimalistic culture condi-
ions.
Cholesterol represents the major lipid in FBS, much of which
s bound to albumin and to both low- and high-density lipopro-
eins, and is important for maintaining cell integrity and growth in
erum-free culture [76]. Cholesterol has been well-studied for its
ontribution to membrane ﬂuidity, and is a major component of
ipid rafts that have recently been described as regulating struc-
ures of embryonic stem cell self-renewal [77]. It has also been
hown to inﬂuence osteogenic differentiation in MSCs [78]. The
ifﬁculty with replacing cholesterol in chemically-deﬁned media
s twofold. It has limited solubility in aqueous solutions, an issue
esolved when bound to a carrier protein such as albumin, and
t is primarily sourced from animal-derived materials such as
heep’s wool. Therefore, this raw material must be synthetically
erived if included in an animal-free medium, and formulated
n such a way to ensure solubility and stability. Approaches
nclude cyclodextrin encapsulation, liposome formation, emulsions
79–81] and synthetic cholesterols such as SyntheCholTM supple-
ent (Sigma–Aldrich).
There is strong interplay between the trace elements present
n cell culture media; many trace elements are typically bound
o proteins found in FBS and may  thereby be lacking in serum-
ree formulations. Iron, copper, zinc and selenium are the main
race elements in culture media and participate in a variety of
ellular functions, often as enzyme cofactors. A recent study by
ryan et al. not only established variations in donor-to-donor trace
lement composition of FBS, but also linked this variation to differ-
nces in protein expression of primary umbilical vein endothelial
ells [82], in particular to that of CD54, a non-standard hMSC
arker [83]. Iron is present as a salt in many classical media for-
ulations that can be delivered and regulated by the transferrin
resent in FBS. However, in the absence of transferrin, iron salts
re unable to enter the cell and thus must be substituted with
 bioavailable source of chelated iron such as ferric ammonium
itrate [84]. The use of chelated iron in the absence of transfer-
in must be carefully optimized to avoid iron-mediated oxidative
tress in the manufacturing of an hMSC therapeutic, as exces-
ive iron has been shown to alter their biological properties [85].
lternatively, inclusion of recombinant transferrin in serum-free
ormulation can provide iron delivery and regulation. Likewise,
opper and zinc are typically bound to proteins in FBS including
nsulin, recombinant forms of which may  lack these essential ele-
ents.eering Journal 108 (2016) 3–13 9
3.4. Growth factors and feed strategy
Perhaps the most critical components to balance properly in
cell culture media for regenerative medicine applications are the
growth factors. Not only do they provide necessary mitogenic input
to non-immortalized cells, but their correct balance is required to
maintain the speciﬁc cellular phenotype desired. bFGF in particu-
lar is often used to enhance cell growth and maintain phenotype,
though it may  not be absolutely necessary to achieve expansion in
the presence of FBS. The exact factors and concentrations thereof
vary among cell types and applications; however, factors such
as bFGF, PDGF-BB and TGF1 are commonly used in serum-free
media for the expansion of hMSCs [86]. One of the most com-
prehensive serum-free media optimization studies published to
date, by Jung et al. [87] explored these and other growth factors
including EGF, HGF and FGF4. A mix  of growth factors, hormones,
as well as insulin, transferrin and notably human serum albumin
was found necessary for hMSC serial passaging and expression
of cell surface markers. Reliable sourcing of these materials may
pose a challenge as the manufacturing of growth factors using a
completely animal-free process is not trivial. For example, TGFb1
must be made in a more complex mammalian system such as Chi-
nese hamster ovary (CHO) cells due to required post-translations
modiﬁcations or in human cell expression systems such as the
HumanKine® line of cytokines (HumanZyme) made in proprietary
HEK 293 cells.
Development of an optimized growth factor supplementation
strategy for expansion and retention of desired stem cell phe-
notype and potential is critical for keeping formulations simple
and cost-effective. Considering the short half-life of many of these
factors, feed strategies for scale up in suspension systems need
to be optimized as media exchange becomes more complicated
versus planar culture where 100% of the medium is typically
changed every 2–4 days. In smaller scale vessels such as spinner
ﬂasks, batch culture will typically maintain hMSCs for approxi-
mately 4–6 days. The inclusion of a 50% media exchange to the
process, at day 4 for example, can extend the culture to approxi-
mately 6–8 days; longer cultures are possible with additional media
exchanges [38]. Not only does this replenish critical components
such as the growth factors, but also dilutes accumulated metabo-
lites including ammonia and lactate, and may allow for greater cell
densities.
In larger scale reactors in which upwards of a 40-fold increase
in hMSC cell number can be achieved [36], cultures are typically
started either at the minimum working volume or half the maxi-
mum  volume of the reactor. Fresh media and microcarriers are then
added at designated points in the culture, either based on culture
time or as the result of a predeﬁned metabolic trigger (e.g., glucose
level) [88], until the maximum volume is reached. At this point,
small additions of concentrated nutrients such as growth factors,
glucose and/or glutamine can continue to be added as needed. This
scale up and feed approach serves to dilute metabolites, maintain
nutrients and growth factor concentrations, and can extend culture
duration up to 10–14 days for hMSCs. Perfusion is another approach
that can be used to extend the growth phase of microcarrier-based
suspension cultures and has been demonstrated for hMSCs utilizing
a proprietary xeno-free media formulation [37].
4. Downstream processing
Downstream processing in a cell therapy manufacturing pro-
cess is fairly simple consisting of removal and separation of the
cells from the growth surface, concentration of the cells and refor-
mulation, usually into a cryopreservative. These steps become
increasingly complex as a process transitions from planar culture to











































aig. 3. Process for harvesting cells from microcarrier-based suspension cultures. V
ncluding both normal ﬂow and alternating tangential ﬂow ﬁltration, as well as con
icrocarrier based bioreactor culture and as the process is scaled up
o large volumes. At each processing step care must be taken to pre-
erve the viability of the cells while maximizing yield and ensuring
hat no contaminants enter the cell product. More detail regarding
ach of the steps and current technologies in use for downstream
rocessing is described in this section.
.1. Detachment of cells from microcarriers
Just as important as the culture medium in which cells for ther-
peutic use are cultivated, is the surface upon which they are
rown. Cultivation of anchorage-dependent cells such as MDCK,
ERO or certain CHO cell lines on microcarriers has been used for
accine and antibody production. However, because the ﬁnal bio-
herapeutic in these instances is secreted by cells into the culture
edium, detachment and separation of cells from microcarriers is
ot required. The culture surface properties can greatly impact the
bility to achieve this detachment. An extracellular matrix (ECM)
omponent coating or surface charge aids in attachment of the
ells, which in turn deposit their own ECM as they expand on
he culture surface. Some cultureware such as CellBind® surfaces
Corning) are modiﬁed to improve cellular attachment, in this case
y increasing oxygen-containing functional groups rendering the
urface more hydrophilic. In cellular migration models, exogenous
actors including TGFb1 and PDGF-BB have been shown to alter
dhesion and migration capacity of MSCs [89,90], highlighting the
omplex interaction between media formulation and surface com-
osition. Typical detachment approaches include proteases such
s trypsin, cationic chelating agents such as EDTA, increased pH
91], application of mild hydrodynamic forces or some combina-
ion thereof. For example, Nienow et al.recently reported a harvest
ethod for hMSCs grown on plastic microcarriers that includes agi-
ation in the cell detachment step in order to minimize the duration
f enzymatic exposure [92]. Detachment reagent concentration and
etachment time should be carefully optimized to enable the max-
mum recovery of cells while preserving the quality of hMSCs for
herapeutic use with respect to viability and cell surface character-
stics [93], as well as other functional attributes. Stepping toward
n enzymatic-free process, a thermoresponsive hydrogel surface
aterial was described that sustained enzymatic-free passaging of
dipose-derived hMSCs with retention of key cell characteristics
94]. Application of such technology to a microcarrier format could
reatly ease the current challenges in cell-microcarrier detachment
nd separation [95] for a more streamlined process.s approaches are under evaluation for the separation of cells from microcarriers,
us centrifugation.
4.2. Separation of cells from microcarriers
Several technologies are available for the separation of cells from
their expansion surface. Whereas enzymatic detachment alone is
sufﬁcient to separate cells from a planar culture system, cells grown
in suspension require the development of methodologies to ensure
efﬁcient separation of cells from microcarriers. Furthermore, it is
essential that the ﬁnal cell therapy product meet the regulatory and
safety standards for particulates (e.g., USP <788>) for injectable and
parenterally infused drugs. Cell therapy products have a unique set
of challenges with regard to particulates, as they are more exten-
sively processed than blood transfusion products, yet they lack
the downstream ﬁltration steps of protein biologic production that
can remove particulates. Development and application of appropri-
ate methods, standards and regulations with respect to particulate
removal is an ongoing topic for the cell therapy ﬁeld [96].
Microcarriers are larger than MSCs (generally ∼150–200 m
compared to 15–20 m,  respectively) and can be ﬁltered from cells
via size exclusion after the cells are detached. For small scale pro-
cesses, devices are available from BD or EMD  Millipore with nylon
ﬁlters and mesh sizes of 40–100 m that are often employed to
separate hMSCs from microcarriers [38,97,98], but as larger scale
processes are envisioned a more scalable solution is required. Dead
end or normal ﬂow (NF) ﬁltration with larger nylon mesh ﬁlters
(Harvestainer, HyClone) or membrane ﬁlters (Opticap® Polygard®-
CR 100, EMD  Millipore) are feasible options for moderate scales
(3–200 L), and are simple and cost-effective single-use options.
However, to avoid fouling at scales greater than 200 L, more sophis-
ticated harvest systems may  need to be employed. Alternating
tangential ﬂow (ATF) ﬁltration offers a possible way to keep micro-
carriers from fouling the mesh screen (Fig. 3). Repligen offers a
variety of devices from the ATFTM 2 to the ATFTM 10 which can
harvest microcarrier process scales from 1 L to 5000 L. Many of
these separation tools, including the ATFTM device, currently need
to be autoclaved or steamed in place, adding additional process and
validation work to be performed by the end-user.
Continuous ﬂow centrifugation is another option for microcar-
rier separation. KBI Biopharma’s kSep® centrifuge systems offer
closed, single-use contact surfaces and can sediment up to 6 L of
microcarriers per cycle, corresponding to approximately 250 L of
culture with 15 g/L of microcarriers. While the current system is
well-suited for use with cell suspensions, modiﬁcations may  be
needed for use with higher concentrations of microcarriers. Thus,
normal ﬂow ﬁltration with a mesh between 40 and 100 m may
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evelopment may  be needed. In all cases it must be demonstrated
hat the method used to separate the cells from the microcarriers
s capable of safe and effective clearance of microcarriers from the
nal drug product.
.3. Cell concentration
It is estimated that for some indications up to 250 million cells
er dose will be required [3]. In a 5 mL  injection dose example, a
ell concentration of 50 million cells/mL may  be needed. Available
echnologies for the concentration or volume reduction of cells fol-
owing microcarrier separation depend greatly on the scale of the
rocess and the required volumetric reduction. Currently, small-
cale centrifugation is effective for volumes up to approximately
en liters, but becomes cumbersome thereafter. The kSep® prod-
cts previously mentioned enable process volumes up to 6000 L
nd can sediment up to 1.2 × 109 cells. Without microcarriers in
he ﬂow path, the chance of clogging is greatly reduced. The vol-
me  reduction (fold concentration) would depend greatly on the
ioreactor feed, but for the kSep®400 system volume reductions
f 100-fold may  be possible from a 200 L bioreactor. Another pos-
ibility is the ATFTM device with hollow ﬁber membrane options
han can concentrate the cells after they have been separated from
he microcarriers. These ATFTM membranes are designed for per-
usion, so they may  need to be oversized to accommodate the ﬂow
ates necessary to perform the volume reduction in less than 8 h in
rder to maintain high viability. Tangential ﬂow ﬁltration offers a
hird type of technology that can be used to concentrate cells for
herapeutic use. Open channel TFF products like the Pellicon® or
rostackTM cassettes from EMD  Millipore utilize large ﬂow paths
or the cells to ﬂow through while permeate is removed. Like the
TFTM offerings, pre-sterilization is a hurdle that needs to be over-
ome by vendors for these devices to best serve the cell therapy
ndustry.
.4. Cryopreservation
The drive towards clinical applications of allogeneic hMSCs has
ed to the reappraisal of conditions under which cells are preserved
o ensure their safety and retain their potency. Cells for immediate
se can be formulated differently than those that need to be cryop-
eserved. For hMSCs that need cryopreservation, one must select
 medium and cryopreservative, develop a freezing protocol and
ecure stable storage in liquid nitrogen facilities [99]. Typical cry-
preservation solutions are a mixture of cell growth medium and
MSO. However, there is mounting desire to remove both animal-
erived materials present in some growth medium formulations
nd the DMSO used as the cryopreservative for clinical-grade stem
ell banking, as there is evidence that DMSO is toxic to humans
t high concentrations [100]. Thus, initial efforts have focused on
educing the concentration of DMSO required to achieve cryop-
eservation effectiveness. Replacing DMSO with alternatives such
s glycerol, sucrose, and/or high molecular weight polymers such
s polyvinylpyrollidone for cryopreservation of hMSCs is an area of
urrent research [101]. An additional factor that is critical for suc-
essful cryopreservation and subsequent recovery of cells, is the
bility to control the rate at which cells are frozen. Controlled-rate
reezers are suitable for controlling temperature [102], however
ome units are lacking and thus it is difﬁcult to ensure that all
ials have been processed identically during large-scale banking
f MSCs [101]. Hence, there is a need to develop controlled-rate
reezers that can effectively accommodate large scale banking as
ell. Together these variables contribute to the stability of cells,
nd thereby their successful ﬁnal use in patients and as such their
ontinued reﬁnement is critical.eering Journal 108 (2016) 3–13 11
5. Conclusions
Although hurdles remain for bringing safe and effective stem
cell therapies for the beneﬁt of patients, great strides has been
made in the development of materials and processes to achieve
this goal. hMSCs may  be particularly well-suited as an allogeneic
therapy due to their intrinsic immune-regulatory properties, and
serve as a primary model for manufacturing platform develop-
ment. Ultimately, cost-effective, closed-systems using high quality
reagents with enough ﬂexibility to address the needs of multiple
cell types are desirable. Fundamental investigations into the inﬂu-
ences of culture surface chemistry, hydrodynamic forces and media
components on stem cell biology are helping to guide this devel-
opment. More than ever, close collaboration between hardware,
consumables and reagent manufacturers, and academic and clinical
investigators will be required to facilitate this process if success-
ful cell-based therapies are to be realized. Moreover, although the
various phases of therapeutic production are often developed in
isolation, it will be important to consider downstream challenges
while establishing upstream parameters. This is especially true
concerning the development of relevant analytics and lot release
testing for which a deeper understanding of the mechanism of
action of cells used as therapeutics may  be required. Ongoing and
future trials with hMSCs and other cell types will be an important
clinical setting for advancement of this basic knowledge around the
efﬁcacy of stem cell therapy.
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